Evidence map›Paper›PMID 40889888›Full record

SynthesisFamily medicine and community health2025

Trial-based economic evaluations of non-drug interventions in the Royal Australian College of General Practitioners (RACGP) Handbook of Non-Drug Interventions in primary care: a systemic review.

Tiffany Atkins, Darryn Marks, Caroline Dowsett, Paul Glasziou, Loai Albarqouni

Abstract readSystematic Review
In one paragraph

Synthesis in Family medicine and community health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tiffany AtkinsInstitute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia.ORCID 0009-0007-4564-6859
Darryn MarksInstitute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia.
Caroline DowsettInstitute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia.ORCID 0000-0001-7734-9436
Paul GlasziouInstitute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia.
Loai AlbarqouniInstitute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia lalbarqo@bond.edu.au.ORCID 0000-0002-4114-9106

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis systematic review assessed trial-based economic evaluations to provide empirical evidence on the cost-effectiveness of non-drug interventions (NDIs) that are currently recommended within the Royal Australian College of General Practitioners Handbook of Non-Drug Interventions (HANDI).

methodsMedline, CINAHL and PsycINFO along with clinical trial registries (clinicaltrials.gov and WHO International Clinical Trials Registry Platform) were searched from inception to 1 July 2025. Randomised controlled trials (RCTs) that reported cost effectiveness for a prescribed non-drug intervention (NDI) from HANDI were included in the study. The primary outcome was the incremental cost-utility ratio (ICUR) derived from cost-utility analyses (CUAs).

resultsA total of 11 187 citations were identified, from which 156 RCTs were included. These RCTs enrolled a total of 66 926 participants (median=214, IQR 139-342), with a median follow-up duration of 12 months (IQR 6-12 months). Over half of the CUA NDIs were for mental health conditions (n=81; 54.0%), one-third were for were for musculoskeletal conditions (n=44; 29.3%), while only 16.0% (n=24) were for those with cardiovascular/metabolic conditions. Out of the 150 NDIs that reported CUAs, 40% were deemed to be in the south-east (SE) quadrant (cheaper and more effective) and 49.3% fell in the north-east (NE) quadrant (more costly but more effective), with 70% considered cost effective against a £25 000/quality-adjusted life-year (QALY) willingness to pay threshold. The overall median ICUR was £2400/QALY (IQR -18 986 to 20 027).

conclusionsMost of the HANDI NDIs that were included within this systematic review are cost-effective compared with a variety of alternatives including usual care or waiting list controls. HANDI NDIs warrant use as a first line of treatment when clinically appropriate.

Indexed as

Cost-Benefit AnalysisPrimary Health CareAustraliaHumansRandomized Controlled Trials as TopicDiet, Food, and NutritionFamily MedicineGeneral Practice

Identifiers

PMID40889888
PMCPMC12406924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.